KaramChucriMounzerMD

Infectious Disease • Philadelphia, PA

Physician

Join to view full profile

Dr. Mounzer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mounzer's full profile

Already have an account?

Office
1233 Locust St
Fl 4
Philadelphia, PA 19107
Phone+1 215-790-1788

Fax+1 215-732-5490

Education & Training

Cooper Medical School of Rowan University/Cooper University HospitalFellowship, Infectious Disease, 1995 - 1997
Cooper Medical School of Rowan University/Cooper University HospitalResidency, Internal Medicine, 1992 - 1995
St Joseph's University Medical SchoolClass of 1992

Certifications & Licensure

PA State Medical License 1995 - 2024
NJ State Medical License 1995 - 2005
DE State Medical License 1997 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects Start of enrollment: 2005 Jul 01
Terminated
Phase 2
Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection Start of enrollment: 2008 Jan 01
Completed
Phase 2
Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV Start of enrollment: 2013 Aug 07
Completed
Phase 2
Reducing Proviral HIV DNA With Interferon-a Start of enrollment: 2015 Feb 11
Unknown status
Phase 2
Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2) Start of enrollment: 2020 Jun 18
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Cognate antigen engagement induces HIV-1 expression in latently infected CD4T cells from people on long-term antiretroviral therapy.
Milica Moskovljevic, Filippo Dragoni, Nathan L Board, Fengting Wu, Jun Lai
Immunity. 2024-12-10
Real world virologic outcomes in patients with elevated body mass index receiving long acting cabotegravir/rilpivirine.
Christina Maguire, Kaitlyn Rueve, Eric Farmer, Emily Huesgen, Antoneta Karaj
Clinical Infectious Diseases. 2024-11-27
Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex Human Immunodeficiency Virus Treatment Regimen: A Randomized, Open-Label, Multice...
Karam Mounzer, Jihad Slim, Moti Ramgopal, Malcolm Hedgcock, Mark Bloch
Clinical Infectious Diseases. 2024-11-26